# Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B

> **NCT03855280** · PHASE3 · COMPLETED · sponsor: **Medexus Pharma, Inc.** · enrollment: 21 (actual)

## Conditions studied

- Hemophilia B

## Interventions

- **DRUG:** APVO101

## Key facts

- **NCT ID:** NCT03855280
- **Lead sponsor:** Medexus Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-16
- **Primary completion:** 2022-07-04
- **Final completion:** 2022-07-04
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03855280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03855280, "Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03855280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*